SCHEMBL5376246

SCHEMBL5376246

N[C@@H]1C[C@H](N)CN(c2nc(Nc3ccc(NC(=O)c4ccc5cccnc5c4O)c(O)c3)nc(N3C[C@H](N)C[C@H](N)C3)n2)C1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 15/20 0.46
KDR P35968 3/20 0.40
KDM6A O15550 1/20 0.40
KDM4E B2RXH2 1/20 0.40
KDM6B O15054 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
KDM5C P41229 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
HIF1AN Q9NWT6 1/20 0.40
KDM2A Q9Y2K7 1/20 0.40
KDM3A Q9Y4C1 1/20 0.40
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376284 1.00 EGLN1 (0.46) EGLN1KDRKDM6AKDM4EKDM6B
SCHEMBL5446978 0.92 EGLN1 (0.45) EGLN1KDR
SCHEMBL5446999 0.92 EGLN1 (0.45) EGLN1KDR
SCHEMBL5392253 0.90 EGLN1 (0.56) EGLN1KDRKDM6AKDM4EKDM6B
SCHEMBL5382599 0.88 KDM6A (0.36) EGLN1KDM6AKDM4EKDM6BMAOA
SCHEMBL5382983 0.88 TERT (0.40)
SCHEMBL14505201 0.86 EGLN1 (0.49) EGLN1KDRKDM4E
SCHEMBL5380610 0.85 PIM1 (0.42)
SCHEMBL5384742 0.84 KDR (0.40) KDR
SCHEMBL5391098 0.84 KLKB1 (0.41) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-7223759-B2 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20050239827-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds ANADYS PHARMACEUTICALS, INC. 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds DDC, DPP3, AMPD3 EGLN1 2481/4885KDR 4684/4885KDM6A 2353/4885
US-20050239827-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds AMPD3, AAAS, PEPD EGLN1 1525/4885KDR 4720/4885KDM6A 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.